Lantern Pharma is trading 10.32% up at $1.71 after-hours, with no clear company-specific catalyst identified.
- Shares closed at $1.55 on September 18, 2026, following a 9.36% regular-session decline.
- The latest announcement concerns a September 23 webinar about Open-Medicine AI’s business model and roadmap, which is forward-looking rather than an evident immediate catalyst.
- Broader markets were mixed-to-positive, but the move remains unexplained.